A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
== D == D-arabinitol 2-dehydrogenase - D-arabinose 1-dehydrogenase (NAD(P)+) - database search - degeneracy (biology) - deletion - denaturation - denaturing gel - deoxyribonuclease (DNase) - deoxyribonucleic acid - deoxyribonucleotide - deoxyuridine phosphorylase - diabetes mellitus - dideoxy sequencing - dideoxyribonucleotide - diethyl 2-methyl-3-oxosuccinate reductase - dihydrochelirubine 12-monooxygenase - dimethyl sulfide:cytochrome c2 reductase - diploid - direct repeat - directionality - DLG2-AS1 - DNA ligase -DNA Bank - DNA polymerase - DNA replication - DNA sequencing - DNase - dominant - dot blot - double helix - downstream (DNA) - downstream (transduction) - drimenol cyclase- ds - duplex -
Micellar electrokinetic chromatography (MEKC) is a chromatography technique used in analytical chemistry. It is a modification of capillary electrophoresis (CE), extending its functionality to neutral analytes, where the samples are separated by differential partitioning between micelles (pseudo-stationary phase) and a surrounding aqueous buffer solution (mobile phase). The basic set-up and detection methods used for MEKC are the same as those used in CE. The difference is that the solution contains a surfactant at a concentration that is greater than the critical micelle concentration (CMC). Above this concentration, surfactant monomers are in equilibrium with micelles. In most applications, MEKC is performed in open capillaries under alkaline conditions to generate a strong electroosmotic flow. Sodium dodecyl sulfate (SDS) is the most commonly used surfactant in MEKC applications. The anionic character of the sulfate groups of SDS causes the surfactant and micelles to have electrophoretic mobility that is counter to the direction of the strong electroosmotic flow. As a result, the surfactant monomers and micelles migrate quite slowly, though their net movement is still toward the cathode. During a MEKC separation, analytes distribute themselves between the hydrophobic interior of the micelle and hydrophilic buffer solution as shown in figure 1. Analytes that are insoluble in the interior of micelles should migrate at the electroosmotic flow velocity,
==== GBA gene ==== The GBA gene is associated with lysosome storage and autophagy. GBA encodes the enzyme glucocerebrosidase (GCase), necessary for breaking down glucosylceramide (GlcCer). Mutations in GBA can cause modifications in GCase protein structure, decreases in GCase activity and protein levels, and the accumulation of GlcCer in the cell. Approximately 5–15% of PD patients have mutations in the GBA gene. Mendelian genetics are not strictly observed in GBA mutations in PD. Both gain-of-function and loss-of-function GBA mutations are associated with increased risk of PD. GBA is one of a number of pleiotropic genes which have multiple effects in the body, that have been linked to PD risk. Mutations in GBA1 can cause either complete loss‐of‐function and the lysosomal disorder Gaucher's disease, or partial loss‐of‐function with an increased risk for PD. Mutations in EPG5 are implicated in a range of dysfunctions, from severe (Vici syndrome), to moderate (atypical parkinsonism) and mild (typical PD). Microdeletions at 22q11.2 have been variously linked to PD, schizophrenia, and DiGeorge syndrome.
Sources: en.wikipedia.org
=== Regulation === PCP is a Schedule II substance in the US. The Administrative Controlled Substances Code Number (ACSCN) for PCP is 7471. Its manufacturing quota for 2014 was 19 grams (0.67 oz). It is a Schedule I drug by the Controlled Drugs and Substances act in Canada, a List I drug of the Opium Law in the Netherlands, and a Class A substance in the UK.
== Acquisition == In June 2013, Amgen offered to buy the shares of Onyx Pharmaceuticals for US$120 per share, sending the shares up by around 30% after the news was announced. Onyx announced on June 30, 2013, that it had rejected the unsolicited proffer from Amgen and its board of directors had subsequently authorized their financial advisers to contact other potential acquisition suitors. However after a series of efforts to secure a higher per-share price from other potential buyers repeatedly failed to materialize, the board reversed course and agreed to Amgen's original terms; the acquisition was formally announced on August 25, 2013.
There are several different types of germs that have developed a resistance over time. The six pathogens causing most deaths associated with resistance are Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. They were responsible for 929,000 deaths attributable to resistance and 3.57 million deaths associated with resistance in 2019. Penicillinase-producing Neisseria gonorrhoeae developed a resistance to penicillin in 1976. Another example is Azithromycin-resistant Neisseria gonorrhoeae, which developed a resistance to azithromycin in 2011. In gram-negative bacteria, plasmid-mediated resistance genes produce proteins that can bind to DNA gyrase, protecting it from the action of quinolones. Finally, mutations at key sites in DNA gyrase or topoisomerase IV can decrease their binding affinity to quinolones, decreasing the drug's effectiveness. Some bacteria are naturally resistant to certain antibiotics; for example, gram-negative bacteria are resistant to most β-lactam antibiotics due to the presence of β-lactamase. Antibiotic resistance can also be acquired as a result of either genetic mutation or horizontal gene transfer. Although mutations are rare, with spontaneous mutations in the pathogen genome occurring at a rate of about 1 in 105 to 1 in 108 per chromosomal replication, Bacteria reproduce at a high rate, lifespans and production of new generations can be on a timescale of mere hours.
In 2012 and 2014, the Aspen Institute named Santa Fe College one of the ten best community colleges in the U.S. In 2015, the college received the Aspen Prize for Community College Excellence, recognizing it as the top community college in the country. In 2015, the Lawrence W. Tyree Library received the Excellence in Academic Libraries Award from the Association of College & Research Libraries.
Sources: en.wikipedia.org
The mRNA is loaded onto the ribosome and is read three nucleotides at a time by matching each codon to its base pairing anticodon located on a transfer RNA molecule, which carries the amino acid corresponding to the codon it recognizes. The enzyme aminoacyl tRNA synthetase "charges" the tRNA molecules with the correct amino acids. The growing polypeptide is often termed the nascent chain. Proteins are always biosynthesized from N-terminus to C-terminus. The size of a synthesized protein can be measured by the number of amino acids it contains and by its total molecular mass, which is normally reported with the unit dalton (Da), or its derivative unit kilodalton (kDa). The average size of a protein increases from Archaea to Bacteria to Eukaryote (283, 311, 438 residues and 31, 34, 49 kDa respectively) due to a bigger number of protein domains constituting proteins in higher organisms. For instance, yeast proteins are on average 466 amino acids long and 53 kDa in mass. The largest known proteins are the titins, a component of the muscle sarcomere, with a molecular mass of almost 3000 kDa and a total length of almost 27000 amino acids.
Chlorpromazine has been found to increase propranolol levels by 1.7-fold. The non-selective CYP450 inhibitor cimetidine has been found to increase peak propranolol levels by 1.4-fold and area-under-the-curve levels by 1.5-fold. Cigarette smoking, which induces CYP1A2, has been found to increase the clearance of propranolol by 77%, resulting in decreased propranolol concentrations. The lipid-lowering drugs cholestyramine and colestipol decreased propranolol levels by up to 50%. Aluminum hydroxide gel may decrease propranolol levels. Alcohol may increase propranolol levels.
=== Legal status === Tividenofusp alfa was approved for medical use in the United States in March 2026. The US Food and Drug Administration (FDA) granted the application for tividenofusp alfa breakthrough therapy, fast track, priority review, and orphan drug designations. The FDA granted accelerated approval for Avlayah to Denali Therapeutics.
Anna, these actions were "an unparalleled act of violence and unprecedented human rights abuse." It is very certain that this popular unrest was one of the causes for the riots that surrounded the dismissal of Monteagudo on July 25, 1822, since it was perceived, in the feelings of the Lima population of all social classes, as a very unfair act because it is an abuse against Spaniards who had lived in Peru for decades and who had an important social and economic role. According to Scarlett O'Phelan, Monteagudo's measures were about to generate the annihilation of the social group of merchants who were active in very important areas for the Peruvian economy (these being agriculture and, above all, mining). This was due to the fact that the large, small, and medium-sized owners (all expropriated without much difference) were responsible for managing the most vital aspects of the viceroyalty's economy. It is also known that battalions of Argentine origin generated complaints from the civilian population due to the "havoc and exhortations" they carried out on the farms, devastating the crops and even attacking (sometimes seriously injuring) a large part of the members of the Peasant, who worked the land.
== Breeding == Potatoes, both S. tuberosum and most of its wild relatives, are self-incompatible: they bear no useful fruit when self-pollinated. This trait is problematic for crop breeding, as all sexually produced plants must be hybrids. The gene responsible for self-incompatibility, as well as mutations to disable it, are now known. Self-compatibility has successfully been introduced both to diploid potatoes (including a special line of S. tuberosum) by CRISPR-Cas9. Plants having a 'Sli' gene produce pollen which is compatible to its own parent and plants with similar S genes. This gene was cloned by Wageningen University and Solynta in 2021, which would allow for faster and more focused breeding. Diploid hybrid potato breeding is a recent area of potato genetics supported by the finding that simultaneous homozygosity and fixation of donor alleles is possible. Wild potato species useful for breeding blight resistance include Solanum desmissum and S. stoloniferum, among others.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.